• LAST PRICE
    5.1250
  • TODAY'S CHANGE (%)
    Trending Down-0.1950 (-3.6654%)
  • Bid / Lots
    5.1200/ 6
  • Ask / Lots
    5.1300/ 4
  • Open / Previous Close
    5.2400 / 5.3200
  • Day Range
    Low 4.9901
    High 5.2400
  • 52 Week Range
    Low 4.9100
    High 11.9100
  • Volume
    1,142,840
    average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Tuesday's close: 5.32
TimeVolumeEDIT
09:32 ET535855.15
09:34 ET289765.11
09:36 ET83415.1
09:38 ET128655.11
09:39 ET72265.095
09:41 ET81345.07
09:43 ET112845.05
09:45 ET84525.04
09:48 ET421515.02
09:50 ET244525.03
09:52 ET201415.05
09:54 ET115875.03
09:56 ET134215
09:57 ET745335.015
09:59 ET177635.02
10:01 ET124485.02
10:03 ET63605.03
10:06 ET53665.055
10:08 ET66545.085
10:10 ET105115.09
10:12 ET55125.1093
10:14 ET218685.085
10:15 ET45005.09
10:17 ET68645.1
10:19 ET93935.12
10:21 ET40685.095
10:24 ET216885.085
10:26 ET95305.085
10:28 ET46895.075
10:30 ET68005.075
10:32 ET68835.055
10:33 ET99445.04
10:35 ET70965.05
10:37 ET150715.075
10:39 ET67395.095
10:42 ET92285.13
10:44 ET88265.1299
10:46 ET176385.11
10:48 ET54845.145
10:50 ET172775.15
10:51 ET38745.125
10:53 ET21415.115
10:55 ET44275.115
10:57 ET21345.12
11:00 ET163055.1197
11:02 ET34965.12
11:04 ET18005.12
11:06 ET104665.12
11:08 ET61635.11
11:09 ET89415.095
11:11 ET315445.06
11:13 ET39895.085
11:15 ET45365.1
11:18 ET75995.095
11:20 ET32225.105
11:22 ET20565.12
11:24 ET195005.125
11:26 ET170545.15
11:27 ET6005.155
11:29 ET18145.15
11:31 ET11755.135
11:33 ET16435.14
11:36 ET7065.145
11:38 ET23005.155
11:40 ET5005.1599
11:42 ET64765.16
11:44 ET29495.15
11:45 ET12855.135
11:47 ET10735.145
11:49 ET32005.155
11:51 ET17535.155
11:54 ET5005.155
11:56 ET37465.165
11:58 ET27125.1709
12:00 ET29195.195
12:02 ET42825.186
12:03 ET26495.185
12:07 ET17005.17
12:09 ET6005.175
12:12 ET77005.185
12:14 ET10715.165
12:16 ET38005.16
12:18 ET27745.165
12:20 ET31125.165
12:21 ET5815.165
12:23 ET11875.16
12:25 ET9005.155
12:27 ET122245.155
12:30 ET48165.155
12:32 ET12615.155
12:34 ET18965.1646
12:36 ET8915.15
12:38 ET24365.15
12:39 ET16005.1473
12:41 ET103505.145
12:43 ET19055.145
12:45 ET13005.145
12:48 ET22065.155
12:50 ET1005.155
12:52 ET4745.155
12:54 ET12785.16
12:56 ET23025.16
12:57 ET5535.15
12:59 ET4005.155
01:01 ET170225.15
01:03 ET44995.145
01:06 ET17135.125
01:08 ET37285.12
01:10 ET12265.11
01:12 ET18075.1159
01:14 ET24945.125
01:15 ET18505.125
01:17 ET99605.145
01:19 ET7005.145
01:21 ET40845.155
01:24 ET2005.155
01:26 ET36685.15
01:28 ET4005.155
01:30 ET20365.165
01:32 ET12265.165
01:33 ET37155.14
01:35 ET71255.12
01:37 ET26945.135
01:39 ET6005.14
01:42 ET11005.13
01:44 ET27005.14
01:46 ET15265.135
01:48 ET408605.125
01:50 ET64785.14
01:51 ET6005.135
01:53 ET24675.12
01:55 ET2005.125
01:57 ET7005.125
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesEDIT
Editas Medicine Inc
437.5M
-2.4x
---
United StatesURGN
Urogen Pharma Ltd
491.7M
-3.9x
---
United StatesFATE
Fate Therapeutics Inc
403.0M
-1.8x
---
United StatesYMAB
Y-mAbs Therapeutics Inc
532.7M
-24.4x
---
United StatesADCT
ADC Therapeutics SA
343.4M
-1.2x
---
United StatesALEC
Alector Inc
494.5M
-3.6x
---
As of 2024-05-29

Company Information

Editas Medicine, Inc. is a clinical-stage genome editing company. The Company is focused on developing potentially transformative genomic medicines to treat a broad range of serious diseases. It has developed a proprietary gene editing platform based on CRISPR technology. CRISPR uses a protein- ribonucleic acid (RNA) complex composed of an enzyme, including either CRISPR associated protein 9 (Cas9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1), bound to a guide ribonucleic acid (RNA) molecule designed to recognize a particular deoxyribonucleic acid (DNA) sequence. It is engaged in the development of vivo administered gene editing medicines, in which the medicine is injected or infused into the patient to edit the cells inside their body. Its lead program, reni-cel, is an experimental ex vivo gene-edited medicine to treat sickle cell disease (SCD), a severe inherited blood disease that causes premature death, and transfusion-dependent beta thalassemia (TDT).

Contact Information

Headquarters
11 Hurley StCAMBRIDGE, MA, United States 02141-2110
Phone
617-401-9000
Fax
302-655-5049

Executives

Independent Chairman of the Board
Emma Reeve
President, Chief Executive Officer, Director
Gilmore O'Neill
Chief Financial Officer, Executive Vice President
Erick Lucera
Executive Vice President, Chief Scientific Officer
Linda Burkly
Senior Vice President, Chief Medical Officer
Baisong Mei

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$437.5M
Revenue (TTM)
$69.4M
Shares Outstanding
82.2M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
2.05
EPS
$-2.10
Book Value
$4.27
P/E Ratio
-2.4x
Price/Sales (TTM)
6.3
Price/Cash Flow (TTM)
---
Operating Margin
-266.85%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.